StreetAlpha.app
Home › Stocks › MLYS

Mineralys Therapeutics, Inc. (MLYS)

Healthcare
$14.48
▼ −0.34%
LAST CLOSE · NOV 17

Mineralys Therapeutics develops lorundrostat, an oral medicine for high blood pressure that is hard to control with other treatments. It last closed at $14.48 on Nov 17, down 0.34% on the day. MLYS last reported earnings on Tue, Aug 11, 2026. The average 12-month price target from 2 analysts is $42.50 (+193.5% from the last close), with a high of $56.00 and a low of $29.00. In the past 30 days there were 6 dark pool prints totaling $7.3M, the largest $1.8M.

AI Auto Pilots
Is MLYS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$370.0M
EPS (diluted)
−$4.30
Valuation
Market cap
$1.3B
88.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$101.3M
At Sep 30
Debt
$100K
At Sep 30
Shareholder equity
$503.8M
Shares outstanding
88.6M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: −$29.8M−$29.8MFY2022FY2023: −$71.9M−$71.9MFY2023FY2024: −$177.8M−$177.8MFY2024FY2025: −$154.7M−$154.7MFY2025

From MLYS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Last report
Aug 11
2026 · Before the open (BMO)
Reported EPS
-$2.85
vs -$0.57 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
±13.6%
Priced in before that report
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated MLYS in the past 90 days, not enough for a consensus
Average 12-month target
$42.50
▲ 193.5% upside

Based on 2 analysts who set a price target on MLYS in the past 90 days. The average target is $42.50, with a high of $56.00 and a low of $29.00, compared with the last close of $14.48.

Low $29.00Avg $42.50High $56.00
Blue marker: last close $14.48
Highest target$56.00
Average target$42.50
Lowest target$29.00
Latest rating changes
UBSInitiated
Oct 12Hold$29
HC Wainwright & Co.Reiterated
Oct 12Buy$56
DateFirmActionRatingPrice target
Oct 12UBSInitiatedHold$29
Oct 12HC Wainwright & Co.ReiteratedBuy$56
Loading…

Technical Analysis

MLYS · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 22% below its 20 day and 52% below its 50 day average. It is 80% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $14.30, and the nearest resistance the Pivot at $14.52.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.1%/day
Key levels
$45.6252 week high+215.1%
$25.99200 day average+79.5%
$24.57100 day average+69.7%
$22.0550 day average+52.3%
$17.6020 day average+21.5%
$16.88Swing high (Nov 12)+16.6%
$14.74Pivot R1+1.8%
$14.52Pivot+0.3%
$14.48Last close
$14.3052 week low−1.2%
$14.26Pivot S1−1.5%
Indicators
RSI (14)29.49Oversold below 30Oversold
MACD-2.08Below its signal lineBearish
Stochastic3.5Near the bottom of its rangeOversold
ADX (14)26.0Trending down
Williams %R-97.8Oversold below −80, overbought above −20Oversold
CCI (20)-86.3Oversold below −100, overbought above 100Neutral
Rate of change−9.4%Change over 10 sessionsBearish
ATR (14)$1.32Typical daily range, 9.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MLYS

What happened before

See how MLYS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MLYS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MLYS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MLYS in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
6
Notional
$7.3M
Largest print
$1.8M
Loading…

MLYS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●115 buying vs 101 selling
  • ▼Held by funds -4.0 pts
  • ▼Funds holding -7
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding219226−3.1%
In funds' top 1079−22.2%
Held by funds109.5%113.5%−4.0 pts
New / increased32 / 8333 / 89−5.7%
Reduced / sold out64 / 3765 / 23+14.8%
Put/call ratio0.000.67−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MLYS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MLYS is in one of them and how their past MLYS trades turned out.

MLYS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MLYS in an article yet. Here's the latest on the wider market.

About Mineralys Therapeutics

Mineralys Therapeutics is a biopharmaceutical company based in Radnor, Pennsylvania, that develops medicines for diseases driven by high levels of aldosterone, a hormone that affects blood pressure. Its main product candidate, lorundrostat, is a pill taken by mouth that is being developed to treat high blood pressure, especially cases that do not respond fully to other treatments. The company is also studying lorundrostat in patients with chronic kidney disease and obstructive sleep apnea. Its target patients are adults with high blood pressure, and the company has not yet sold a product.

Headquarters
Radnor, PA